Abstract
The ischaemic penumbra has been documented in the laboratory animal as a severely hypoperfused, non-functional, but still viable cortex surrounding the irreversibly damaged ischaemic core; with elapsing time, more penumbra gets recruited into the core, while tissue reperfusion is able to stop this deleterious process until a certain point in time. As saving the penumbra should improve clinical outcome, it should constitute the main target of acute stroke therapy. In a series of PET studies performed 5–18 h after stroke onset, we were able to (i) document, for the first time in man, the existence of tissue fulfilling operational criteria for penumbra in about one third of the cases; (ii) show that long-term neurological recovery is proportional to the volume of penumbra that eventually escapes infarction, and (iii) detect penumbral tissue as late as 16 h after symptom onset in occasional patients, suggesting the therapeutic window may be protracted in such cases. Mapping the penumbra in the individual patient with neuroimaging procedures should allow to formulate a pathophysiological diagnosis, and thus to design a rational management of the stroke patient and to improve the selection of candidates for therapeutic trials.
References
1.
Astrup J, Symon L, Branston NM, Lassen NA: Thresholds of cerebral ischemia; in Schmiedek P (ed): Microsurgery for Stroke. Berlin, Springer, 1976, pp 16–21.
2.
Astrup J, Siesjö BK, Symon L: Thresholds in cerebral ischemia: The ischaemic penumbra. Stroke 1981;12:723–725.
3.
Lassen NA: Pathophysiology of brain ischemia as it relates to the therapy of acute ischemic stroke. Clin Neuropharmacol 1990;13:S1.
4.
Jones TH, Morawetz RB, Crowell RM, Marcoux FW, FitzGibbon SJ, DeGirolami U, Ojemann RG: Thresholds of focal cerebral ischemia in awake monkeys. J. Neurosurg 1981;54:773–782.
5.
Garcia JH, Mitchem HL, Briggs L, Morawetz R, Hudetz AG, Hazelrig JB, Halsey JH, Conger KA: Transient focal ischemia in subhuman primates: Neuronal injury as a function of local cerebral blood flow. J Neuropathol of Exp Neurol 1983;42:44–60.
6.
Heiss WD, Graf R: The ischemic penumbra. Curr Opin Neurol 1994;7:11-19.
7.
Hossmann KA: Viability thresholds and the penumbra of focal ischemia. Ann Neurol 1994;36:557–565.
8.
Hakim AM: The cerebral ischemic penumbra. Can J Neurol Sci 1987;14:557–559.
9.
Baron JC, Frackowiak RSJ, Herholz K, Jones T, Lammertsma AA, Mazoyer B, Wienhard K: Use of PET methods for measurement of cerebral energy metabolism and hemodynamics in cerebrovascular disease. J Cereb Blood Flow Metab 1989;9:723–742.
10.
Baron JC, Bousser M-G, Comar D, Kellershon C: Human hemispheric infarction studied by positron emission tomography and the 15O continuous inhalation technique; in Caillé JM, Salamon G (eds): Computerized Tomography. 1980, pp 231–237.
11.
Baron JC, Bousser MG, Rey A, Guillard A, Comar D, Castaigne P: Reversal of focal ‘misery-perfusion syndrome’ by extra-intracranial arterial bypass in hemodynamic cerebral ischemia: A case study with 150 positron emission tomography. Stroke 1981;12:454–459.
12.
Ackerman RH, Correia JA, Alpert NM, Baron JC, Gouliamos A, Grotta JC, Brownell GL, Taveras JM: Positron imaging in ischemic stroke disease using compounds labelled with oxygen-15. Arch Neurol 1981;38:537–543.
13.
Baron JC, Bousser MG, Comar D, Soussaline F, Castaigne P: Noninvasive tomographic study of cerebral blood flow and oxygen metabolism in vivo: Potentials, limitations and clinical applications in cerebral ischemic disorders. Eur Neurol 1981;20:273–284.
14.
Lenzi GL, Frackowiak RSJ, Jones T: Cerebral oxygen metabolism and blood flow in human ischemic infarction. J Cereb Blood Flow Metab 1982;2:231–235.
15.
Wise RJS, Bernardi S, Frackowiak RSJ, Legg NJ, Jones T: Serial observations on the pathophysiology of acute stroke: The transition from ischaemia to infarction as reflected in regional oxygen extraction. Brain 1983;106:197–222.
16.
Powers WJ, Grubb RL Jr, Darriet D, Raichle ME: Cerebral blood flow and cerebral metabolic rate of oxygen requirements for cerebral function and viability in humans. J Cereb Blood Flow Metab 1985;5:600–608.
17.
Hakim AM, Pokrupa RP, Villanueva J, Diksic M, Evans AC, Thompson CJ, Meyer E, Yamamoto YL, Feindel WH: The effects of spontaneous reperfusion on metabolic function in early human cerebral infarcts. Ann Neurol 1987;21:279–289.
18.
Heiss WD, Huber M, Fink GR, Herholz K, Pietrzyk U, Wagner R, Wienhard K: Progressive derangement of periinfarct viable tissue in ischemic stroke. J Cereb Blood Flow Metab 1992;12:193–203.
19.
Ackerman RH, Lev MH, Mackay BC, Katz PM, Babikian VL, Alpert NM, Correia JA, Panagos PD, Senda M: PET studies in acute stroke: Findings and relevance to therapy. J Cereb Blood Flow Metab 1989;9 (suppl 1):S359.
20.
Baron JC, Rougemont D, Bousser MG, Lebrun-Grandié P, Iba-Zizen MT, Chiras J: The characteristics of the misery-perfusion syndrome in the acute phase of cerebral infarction; in Lassen NA, Symon L, Baron JC (eds): Pénombre et Ischémie Cérébrale. Paris, Libbey, 1986; pp 25–30.
21.
Marchal G, Serrati C, Rioux P, Petit-Taboue MC, Viader F, De La Sayette V, Le Doze F, Lochon P, Derlon JM, Orgogozo JM, Baron JC: PET imaging of cerebral perfusion and oxygen consumption in acute ischaemic stroke: Relation to outcome. Lancet 1993;341:925–927.
22.
Marchal G, Rioux P, Serrati C, Furlan M, Derlon JM, Viader F, Baron JC: Value of acute-stage positron emission tomography in predicting neurological outcome after ischemic stroke: Further assessment. Stroke 1995;26:524–525.
23.
Marchal G, Furlan M, Beaudoin V, Rioux P, Hauttement JL, Serrati C, De La Sayette V, Le Doze F, Viader F, Derlon JM, Baron JC: Early spontaneous hyperperfusion after stroke: A marker of favourable tissue outcome? Brain 1996;119:409–419.
24.
Marchal G, Beaudouin V, Rioux P, De La Sayette V, Le Doze F, Viader F, Derlon JM, Baron JC: Prolonged persistence of substantial volumes of potentially viable brain tissue after stroke: A correlative PET-CT study with voxel-based data analysis. Stroke 1996;27:599–606.
25.
Furlan M, Marchal G, Viader F, Derlon JM, Baron JC: Spontaneous neurological recovery after stroke and the fate of the ischemic penumbra. Ann Neurol 1996;40:216–226.
26.
Baron JC, Rougemont D, Bousser MG, Lebrun-Gandié P, Iba-Zizen MT, Chiras J: Local CBF, oxygen extraction fraction (OEF), and CMRO2: Prognostic value in recent supratentorial infarction in humans. J Cereb Blood Flow Metab 1983;3 (suppl):S1–S2.
27.
Pappata S, Fiorelli M, Rommel T, Hartmann A, Dettmers C, Yamaguchi T, Chabriat H, Poline JB, Crouzel C, Di Giamberardino L, Baron JC: PET study of changes in local brain hemodynamics and oxygen metabolism after unilateral middle cerebral artery occlusion in baboons. J Cereb Blood Flow Metab 1993;13:416–424.
28.
Touzani O, Young AR, Derlon JM, Beaudoin V, Marchal G, Rioux P, Mézenge F, Baron JC, Mackenzie ET: Sequential studies of severely hypometabolic tissue volumes after permanent middle cerebral artery occlusion: A positron emission tomographic investigation in anesthetized baboons. Stroke 1995;26:2112–2119.
29.
Young AR, Sette G, Touzani O, Rioux P, Derlon JM, MacKenzie ET, Baron JC: Relationships between high oxygen extraction fraction in the acute stage and infarction in reversible middle cerebral artery occlusion: An investigation in anaesthetized baboons with positron emission tomography. J Cereb Blood Flow Metab 1996;16:1176–1188.
30.
Touzani O, Young AR, Derlon JM, Baron JC, MacKenzie ET: Progressive impairment of brain oxidative metabolism reversed by reperfusion following middle cerebral artery occlusion in anaesthetized baboons a quantitative analysis of infarction volume. Brain Res 1997;767:17–25.
31.
Young AR, Touzani O, Derlon JM, Sette G, MacKenzie ET, Baron JC: Early reperfusion in the anesthetized baboon reduces brain damage following middle cerebral artery occlusion. Stroke 1997;28:632–638.
32.
Heiss WD, Graf R, Wienhard K, Lottgen J, Saito R, Fujita R, Rosner G, Wagner R: Dynamic penumbra demonstrated by sequential multitracer PET after middle cerebral artery occlusion in cats. J Cereb Blood Flow Metabol 1994;14:892–902.
33.
Schlaug G, Baird AE, Picone M, Edelman RR, Warach S: Early normalization of the apparent diffusion coefficient (ADC) after reperfusion. Stroke 1998;29:280.
34.
Barber PA, Darby DG, Yang O, Desmond PM, Gerraty RP, Donnan GA, Tress BM, Davis SM: Echoplanar magnetic resonance imaging (EPI) perfusion and diffusion abnormalities correlate with outcome in acute stroke. Stroke 1998;29:307.
35.
Ohyama M, Senda M, Kitamura S, Ishii K, Mishina M, Terashi A: Role of the nondominant hemisphere and undamaged area during word repetition in poststroke aphasics: A PET activation study. Stroke 1996;27:897–903.
36.
Heiss W-D, Karbe H, Weber-Luxenburger G, Herholz K, Kessler J, Pietrzyk U, Pawlik G: Speech-induced cerebral metabolic activation reflects recovery from aphasia. J Neurol Sci 1997;145:213–217.
37.
Cramer SC, Nelles G, Benson RR, Kaplan JD, Parker RA, Kwong KK, Kennedy DN, Finklestein SP, Rosen BR: A functional MRI study of subjects recovered from hemiparetic stroke. Stroke 1997;28:2518–2527.
38.
Engelien A, Silbersweig D, Stern E, Huber W, Doring W, Frith C, Frackowiak RSJ: The functional anatomy of recovery from auditory agnosia: A PET study of sound categorization in a neurological patient and normal controls. Brain 1995;118:1395–1409.
39.
Baron JC, Von Kummer R, Del Zoppo GJ: Treatment of acute ischemic stroke: Challenging the concept of a rigid and universal time window. Stroke 1995;26:2219–2221.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
